Canlyniadau Chwilio - Ramchandren, Radhakrishnan

Advances in the Treatment of Relapsed or Refractory Hodgkin's Lymphoma gan Ramchandren, Radhakrishnan

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia gan Ramchandren, Radhakrishnan, Schiffer, Charles A

Cael y testun llawn Cael y testun llawn

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma gan Johnston, Patrick B., Pinter-Brown, Lauren C., Warsi, Ghulam, White, Kristen, Ramchandren, Radhakrishnan

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study gan Goy, Andre, Sinha, Rajni, Williams, Michael E., Kalayoglu Besisik, Sevgi, Drach, Johannes, Ramchandren, Radhakrishnan, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Witzig, Thomas E.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution gan SUKARI, AMMAR, NAGASAKA, MISAKO, ALHASAN, ROBA, PATEL, DHAVAL, WOZNIAK, ANTOINETTE, RAMCHANDREN, RADHAKRISHNAN, VAISHAMPAYAN, ULKA, WEISE, AMY, FLAHERTY, LAWRENCE, JANG, HYEJEONG, KIM, SEONGHO, GADGEEL, SHIRISH

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma gan Herrera, Alex F., Goy, Andre, Mehta, Amitkumar, Ramchandren, Radhakrishnan, Pagel, John M., Svoboda, Jakub, Guan, Shanhong, Hill, John S., Kwei, Kevin, Liu, Emily A., Phillips, Tycel

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment gan Zhao, Baiteng, Chen, Robert, O'Connor, Owen A., Gopal, Ajay K., Ramchandren, Radhakrishnan, Goy, Andre, Matous, Jeffrey V., Fasanmade, Adedigbo A., Manley, Thomas J., Han, Tae H.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL gan Goy, Andre, Ramchandren, Radhakrishnan, Ghosh, Nilanjan, Munoz, Javier, Morgan, David S., Dang, Nam H., Knapp, Mark, Delioukina, Maria, Kingsley, Edwin, Ping, Jerry, Beaupre, Darrin M., Neuenburg, Jutta K., Ruan, Jia

Cael y testun llawn Cael y testun llawn Cael y testun llawn

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies gan Han, Tae H., Gopal, Ajay K., Ramchandren, Radhakrishnan, Goy, Andre, Chen, Robert, Matous, Jeffrey V., Cooper, Maureen, Grove, Laurie E., Alley, Stephen C., Lynch, Carmel M., O’Connor, Owen A.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) p... gan Goy, Andre, Kalayoglu Besisik, Sevgi, Drach, Johannes, Ramchandren, Radhakrishnan, Robertson, Michael J., Avivi, Irit, Rowe, Jacob M., Herbrecht, Raoul, Van Hoof, Achiel, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Witzig, Thomas

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma gan Witzig, Thomas E., Zinzani, Pier Luigi, Habermann, Thomas M., Tuscano, Joseph M., Drach, Johannes, Ramchandren, Radhakrishnan, Besisik, Sevgi Kalayoglu, Takeshita, Kenichi, Bravo, Marie-Laure Casadebaig, Zhang, Lei, Fu, Tommy, Goy, Andre

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation gan Gopal, Ajay K., Ramchandren, Radhakrishnan, O'Connor, Owen A., Berryman, Robert B., Advani, Ranjana H., Chen, Robert, Smith, Scott E., Cooper, Maureen, Rothe, Achim, Matous, Jeffrey V., Grove, Laurie E., Zain, Jasmine

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study gan Wang, Michael, Ramchandren, Radhakrishnan, Chen, Robert, Karlin, Lionel, Chong, Geoffrey, Jurczak, Wojciech, Wu, Ka Lung, Bishton, Mark, Collins, Graham P., Eliadis, Paul, Peyrade, Frédéric, Lee, Yihua, Eckert, Karl, Neuenburg, Jutta K., Tam, Constantine S.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies gan Bartlett, Nancy L, Chen, Robert, Fanale, Michelle A, Brice, Pauline, Gopal, Ajay, Smith, Scott E, Advani, Ranjana, Matous, Jeffrey V, Ramchandren, Radhakrishnan, Rosenblatt, Joseph D, Huebner, Dirk, Levine, Pamela, Grove, Laurie, Forero-Torres, Andres

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma gan Pro, Barbara, Advani, Ranjana, Brice, Pauline, Bartlett, Nancy L., Rosenblatt, Joseph D., Illidge, Tim, Matous, Jeffrey, Ramchandren, Radhakrishnan, Fanale, Michelle, Connors, Joseph M., Fenton, Keenan, Huebner, Dirk, Pinelli, Juan M., Kennedy, Dana A., Shustov, Andrei

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma gan Dang, Nam H., Ogura, Michinori, Castaigne, Sylvie, Fayad, Luis E., Jerkeman, Mats, Radford, John, Pezzutto, Antonio, Bondarenko, Igor, Stewart, Douglas A., Shnaidman, Michael, Sullivan, Sharon, Vandendries, Erik, Tobinai, Kensei, Ramchandren, Radhakrishnan, Hamlin, Paul A., Giné, Eva, Ando, Kiyoshi

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies gan Forero-Torres, Andres, Ramchandren, Radhakrishnan, Yacoub, Abdulraheem, Wertheim, Michael S., Edenfield, William J., Caimi, Paolo, Gutierrez, Martin, Akard, Luke, Escobar, Carolina, Call, Justin, Persky, Daniel, Iyer, Swaminathan, DeMarini, Douglas J., Zhou, Li, Chen, Xuejun, Dawkins, Fitzroy, Phillips, Tycel J.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma gan Timmerman, John, Herbaux, Charles, Ribrag, Vincent, Zelenetz, Andrew D., Houot, Roch, Neelapu, Sattva S., Logan, Theodore, Lossos, Izidore S., Urba, Walter, Salles, Gilles, Ramchandren, Radhakrishnan, Jacobson, Caron, Godwin, John, Carpio, Cecilia, Lathers, Deanne, Liu, Yali, Neely, Jaclyn, Suryawanshi, Satyendra, Koguchi, Yoshinobu, Levy, Ronald

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma gan Herrera, Alex F., Moskowitz, Alison J., Bartlett, Nancy L., Vose, Julie M., Ramchandren, Radhakrishnan, Feldman, Tatyana A., LaCasce, Ann S., Ansell, Stephen M., Moskowitz, Craig H., Fenton, Keenan, Ogden, Carol Anne, Taft, David, Zhang, Qu, Kato, Kazunobu, Campbell, Mary, Advani, Ranjana H.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma gan Zinzani, Pier Luigi, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A., de Oliveira, Jose S. R., Buccheri, Valeria, Perini, Guilherme Fleury, Dickinson, Michael, McDonald, Andrew, Özcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Raut, Monika, Saretsky, Todd L., Nahar, Akash, Kuruvilla, John

Cael y testun llawn Cael y testun llawn Cael y testun llawn